Table 1.
Clinicopathological features of patients correlated with LCP1 expression detected by immunohistochemistry
| Clinicopathological features | n | LCP1 Expression | P-value | |
|---|---|---|---|---|
| Negative (%) | Positive (%) | |||
| Age at diagnosis | 0.66 | |||
| ≤50 | 14 | 4(28.6) | 10(71.4) | |
| >50 | 15 | 10(66.7) | 5(33.3) | |
| Histological type | 0.083 | |||
| TNBC | 29 | 14(48.3) | 15(51.7) | |
| Benign breast lesions | 11 | 2(18.2) | 9(81.8) | |
| Tumor size | 0.450a | |||
| ≤2cm | 10 | 6 (60.0) | 4 (40.0) | |
| >2cm | 19 | 8 (42.1) | 11 (57.9) | |
| LN metastasis | 0.715 | |||
| YES | 13 | 7 (53.8) | 6 (46.2) | |
| NO | 16 | 7 (43.7) | 9 (56.3) | |
| Clinical stage | 0.639b | |||
| I+II | 23 | 11 (47.8) | 12 (52.2) | |
| III | 6 | 3 (50.0) | 3 (50.0) | |
TNBC Triple-negative breast cancer, NAT Normal adjacent tissue, n Number of cases, LN Lymph node
For comparison of LCP1 protein expression associated with age, tumor size, histological type, lymph node metastasis and clinical stage. Pearson's chi-squared test, Fisher's exact test and Continuous modified chi-square test were applied
aTumor size comparison (≤2 cm vs. >2 cm, TNBC cohort)
bClinical stage comparison (I+II vs. III,TNBC cohort)